VRCI.L Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 Jun 2024 @ 04:13):

Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients...

Stats
Today's Volume	202 269
Average Volume	323 896
Market Cap	18.43M
EPS	£0 ( 2023-10-05 )
Next earnings date	( £0 ) 2024-06-28
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-1.900
ATR14	£0.132 (1.74%)

Verici Dx plc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Verici Dx plc Financials

Annual	2022
Revenue:	£0
Gross Profit:	£0 (0.00 %)
EPS:	£-0.0690

FY	2022
Revenue:	£0
Gross Profit:	£0 (0.00 %)
EPS:	£-0.0690

FY	2021
Revenue:	£0.00
Gross Profit:	£0.00 (0.00 %)
EPS:	£-4.89

Financial Reports:

No articles found.

Verici Dx plc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Verici Dx plc

Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its in-development tests include Clarava, a pre-transplant prognosis test for the risk of early acute rejection; Tuteva, a post-transplant test that focuses on acute cellular rejection; and Protega, a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Penarth, the United Kingdom.